Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zenas BioPharma, Inc. ( (ZBIO) ) has provided an announcement.
On June 10, 2025, Zenas BioPharma, Inc. held its 2025 Annual Meeting of Stockholders. During this meeting, Ting (Tim) Xiao resigned from the Board of Directors, reducing the board size from nine to eight. Stockholders elected Leon O. Moulder, Jr. and Hongbo Lu, Ph.D. as Class I directors for a three-year term and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ZBIO) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
Spark’s Take on ZBIO Stock
According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.
Zenas BioPharma’s overall stock score is driven by its challenging financial performance and valuation concerns, which are partially offset by strong technicals and positive corporate developments. The company’s ability to improve financial stability and capitalize on clinical advancements will be crucial.
To see Spark’s full report on ZBIO stock, click here.
More about Zenas BioPharma, Inc.
Average Trading Volume: 199,477
Technical Sentiment Signal: Strong Buy
Current Market Cap: $499.5M
For a thorough assessment of ZBIO stock, go to TipRanks’ Stock Analysis page.